Table 2.
Baseline patients’ characteristics.
| Study | Male Sex | Age (Years) * | Prior MI | Prior Coronary Revascularization | Diabetes Mellitus | Systemic Hypertension | Dyslipidemia | Active Smoking | ACS as iIdex Rvent | Type of Stent Used |
|---|---|---|---|---|---|---|---|---|---|---|
| WOEST | 448 (79.6%) | EAD: 70.3 ± 7.0 DAPT: 69.5 ± 8.0 |
196 (34.8%) | PCI: 187 (33.2%) CABG: 130 (23.1%) |
140 (24.9%) | 386 (68.6%) | 396 (70.3%) | 102 (18.1%) | 155 (27.5%) | None: 9 (1.6%) DES: 364 (64.6%) BMS: 175 (31.1%) Both: 14 (2.5%) |
| PIONEER AF-PCI | 1581 (74.4%) | EAD: 70.4 ± 9.1 DAPT: 70.0 ± 9.1 and 69.9 ± 8.7 |
477 (22.5%) | - | 624 (29.4%) | 1571 (74.0%) | 913 (43.0%) | 141 (6.6%) | 1096 (51.6%) | DES: 1403 (66.0%) BMS: 675 (31.8%) Both: 40 (1.9%) |
| REDUAL-PCI | 2070 (76.0%) | EAD: 71.5 ± 8.9 and 68.6 ± 7.7 DAPT: 71.7 ± 8.9 |
699 (25.6%) | PCI: 912 (33.5%) CABG: 287 (10.5%) |
993 (36.4%) | - | - | - | 1375 (50.5%) | DES: 2251 (82.8%) BMS: 404 (14.9%) Both: 41 (1.5%) Other: 21 (0.8%) |
| GLOBAL LEADERS | 12,254 (76.7%) | EAD: 64.5 ± 10.3 DAPT: 64.6 ± 10.3 |
3710 (23.2%) | PCI: 5,221 (32.7%) CABG: 943 (5.9%) |
4038 (25.3%) | 11,715 (73.4%) | 10,768 (67.4%) | 4169 (26.1%) | 7487 (46.9%) | Biolimus A9-eluting stent: 94.6% of lesions; other stent in 6.5% of lesions |
| AUGUSTUS | 3277 (71.0%) | EAD: 70.8 (64.4–77.3) DAPT: 70.6 (63.8–77.2) |
- | - | 1678 (36.4%) | 4073 (88.3%) | - | - | 2811 (60.2%) | - |
| STOPDAPT-2 | 2337 (77.7%) | EAD: 68.1 ± 10.9 DAPT: 69.1 ± 10.4 |
406 (13.5%) | PCI: 1032 (34.3%) CABG: 59 (2.0%) |
1159 (38.5%) | 2221 (73.8%) | 2244 (74.6%) | 710 (23.6%) | 1148 (38.2%) | CoCr-EES |
| SMART CHOICE | 2198 (73.4%) | EAD: 64.6 ± 10.7 DAPT:64.4 ± 10.7 |
127 (4.2%) | 349 (11.7%) | 1122 (37.5%) | 1840 (61.5%) | 1352 (45.2%) | 791 (26.4%) | 1741 (58.2%) | CoCr-EES: 1051 (35.1%) PtCr-EES: 967 (32.3%) BP-SES: 972 (32.5%) |
| ENTRUST-AF PCI | 1120 (74.4%) | EAD: 69 (63–77) DAPT: 70 (64–77) |
365 (24.2%) | PCI: 394 (26.2%) CABG: 95 (6.3%) |
517 (34.3%) | 1361 (90.4%) | 981 (65.1%) | - | 777 (51.6 %) | - |
| TWILIGHT | 5421 (76.1%) | EAD: 65.2 ± 10.3 DAPT: 65.1 ± 10.4 |
2040 (28.7%) | PCI: 2998 (42.1%) CABG: 710 (10.0%) |
2620 (36.8%) | 5154 (72.4%) | 4303 (60.4%) | 1548 (21.8%) | 4614 (64.8%) | Locally approved DES |
* Age is provided as mean ± standard deviation or as median [IQR]; MI: myocardial infarction; ACS: acute coronary syndrome; DES: drug eluting stent; BMS: bare metal stent; STEMI: ST segment elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; CoCr-EES: Cobalt-chromium everolimus eluting stent; PtCr-EES: Platinum-chromium everolimus eluting stent; BP-SES: Sirolimus-eluting stent with biodegradable polymer; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; EAD: early aspirin discontinuation group; DAPT: dual antiplatelet therapy group.